End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain
AT Farrell, J Panepinto, CP Carroll, DS Darbari… - Blood …, 2019 - ashpublications.org
To address the global burden of sickle cell disease (SCD) and the need for novel therapies,
the American Society of Hematology partnered with the US Food and Drug Administration to …
the American Society of Hematology partnered with the US Food and Drug Administration to …
End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain
AT Farrell, J Panepinto, CP Carroll, DS Darbari… - Blood Advances, 2019 - Elsevier
To address the global burden of sickle cell disease (SCD) and the need for novel therapies,
the American Society of Hematology partnered with the US Food and Drug Administration to …
the American Society of Hematology partnered with the US Food and Drug Administration to …
[HTML][HTML] End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain
AT Farrell, J Panepinto, CP Carroll, DS Darbari… - Blood …, 2019 - ncbi.nlm.nih.gov
To address the global burden of sickle cell disease (SCD) and the need for novel therapies,
the American Society of Hematology partnered with the US Food and Drug Administration to …
the American Society of Hematology partnered with the US Food and Drug Administration to …
End points for sickle cell disease clinical trials: Patient-reported outcomes, pain, and the brain
AT Farrell, J Panepinto, CP Carroll, DS Darbari… - Blood …, 2019 - kclpure.kcl.ac.uk
To address the global burden of sickle cell disease (SCD) and the need for novel therapies,
the American Society of Hematology partnered with the US Food and Drug Administration to …
the American Society of Hematology partnered with the US Food and Drug Administration to …
End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain
AT Farrell, J Panepinto, CP Carroll… - Blood …, 2019 - pubmed.ncbi.nlm.nih.gov
To address the global burden of sickle cell disease (SCD) and the need for novel therapies,
the American Society of Hematology partnered with the US Food and Drug Administration to …
the American Society of Hematology partnered with the US Food and Drug Administration to …
[PDF][PDF] End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain
AT Farrell, J Panepinto, CP Carroll, DS Darbari… - researchgate.net
Sickle cell disease (SCD) is the most common inherited red blood cell disorder in the United
States, affecting 70 000 to 100 000 Americans. 1 Although the molecular basis of SCD was …
States, affecting 70 000 to 100 000 Americans. 1 Although the molecular basis of SCD was …
End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain
AT Farrell, J Panepinto, CP Carroll, DS Darbari… - Blood …, 2019 - eprints.soton.ac.uk
To address the global burden of sickle cell disease (SCD) and the need for novel therapies,
the American Society of Hematology partnered with the US Food and Drug Administration to …
the American Society of Hematology partnered with the US Food and Drug Administration to …
End points for sickle cell disease clinical trials: Patient-reported outcomes, pain, and the brain
AT Farrell, J Panepinto, CP Carroll, DS Darbari… - Blood …, 2019 - profiles.wustl.edu
To address the global burden of sickle cell disease (SCD) and the need for novel therapies,
the American Society of Hematology partnered with the US Food and Drug Administration to …
the American Society of Hematology partnered with the US Food and Drug Administration to …
End points for sickle cell disease clinical trials: Patient-reported outcomes, pain, and the brain
AT Farrell, AA King - 2019 - digitalcommons.wustl.edu
Sickle cell disease (SCD) is the most common inherited red blood cell disorder in the United
States, affecting 70 000 to 100 000 Americans. 1 Although the molecular basis of SCD was …
States, affecting 70 000 to 100 000 Americans. 1 Although the molecular basis of SCD was …
[PDF][PDF] End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain
AT Farrell, J Panepinto, CP Carroll, DS Darbari… - curesickle.org
Sickle cell disease (SCD) is the most common inherited red blood cell disorder in the United
States, affecting 70 000 to 100 000 Americans. 1 Although the molecular basis of SCD was …
States, affecting 70 000 to 100 000 Americans. 1 Although the molecular basis of SCD was …